Brokerages Set GeneDx Holdings Corp. (NASDAQ:WGS) Price Target at $72.33

GeneDx Holdings Corp. (NASDAQ:WGSGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $72.33.

WGS has been the topic of a number of recent research reports. The Goldman Sachs Group raised their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th.

Check Out Our Latest Stock Report on GeneDx

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 18,006 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08. Following the completion of the transaction, the chief executive officer now owns 53,140 shares in the company, valued at $4,154,485.20. This trade represents a 25.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Feeley sold 1,430 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20. Following the completion of the transaction, the chief financial officer now owns 26,770 shares of the company’s stock, valued at approximately $2,035,590.80. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,735 shares of company stock valued at $11,719,787 in the last quarter. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On GeneDx

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. bought a new position in GeneDx during the third quarter worth $604,000. GSA Capital Partners LLP acquired a new stake in GeneDx during the 3rd quarter worth about $322,000. Royce & Associates LP bought a new position in shares of GeneDx in the 3rd quarter worth about $1,201,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of GeneDx in the 3rd quarter valued at about $2,547,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after purchasing an additional 110,666 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Stock Performance

WGS opened at $94.46 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. The business has a fifty day simple moving average of $84.69 and a 200 day simple moving average of $70.37. GeneDx has a 1 year low of $7.72 and a 1 year high of $115.60.

GeneDx (NASDAQ:WGSGet Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Research analysts expect that GeneDx will post 0.97 EPS for the current year.

GeneDx Company Profile

(Get Free Report

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Stories

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.